60 related articles for article (PubMed ID: 35584359)
41. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
42. Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.
Singh SK; Luisi DL; Pak RH
Pharm Res; 2015 Nov; 32(11):3541-71. PubMed ID: 25986175
[TBL] [Abstract][Full Text] [Related]
43. Advances in the Development of Site-Specific Antibody-Drug Conjugation.
Zhou Q; Kim J
Anticancer Agents Med Chem; 2015; 15(7):828-36. PubMed ID: 25731178
[TBL] [Abstract][Full Text] [Related]
44. Current methods for the synthesis of homogeneous antibody-drug conjugates.
Sochaj AM; Ĺwiderska KW; Otlewski J
Biotechnol Adv; 2015 Nov; 33(6 Pt 1):775-84. PubMed ID: 25981886
[TBL] [Abstract][Full Text] [Related]
45. Practical approaches for overcoming challenges in heightened characterization of antibody-drug conjugates with new methodologies and ultrahigh-resolution mass spectrometry.
Friese OV; Smith JN; Brown PW; Rouse JC
MAbs; 2018 Apr; 10(3):335-345. PubMed ID: 29393747
[TBL] [Abstract][Full Text] [Related]
46. Approaches to Interchain Cysteine-Linked ADC Characterization by Mass Spectrometry.
Valliere-Douglass JF; Hengel SM; Pan LY
Mol Pharm; 2015 Jun; 12(6):1774-83. PubMed ID: 25474122
[TBL] [Abstract][Full Text] [Related]
47. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
Tsuchikama K
Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
[TBL] [Abstract][Full Text] [Related]
48. Site-selective lysine conjugation methods and applications towards antibody-drug conjugates.
Haque M; Forte N; Baker JR
Chem Commun (Camb); 2021 Oct; 57(82):10689-10702. PubMed ID: 34570125
[TBL] [Abstract][Full Text] [Related]
49. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates.
Frigerio M; Kyle AF
Curr Top Med Chem; 2017; 17(32):3393-3424. PubMed ID: 29357801
[TBL] [Abstract][Full Text] [Related]
50. Current Status: Site-Specific Antibody Drug Conjugates.
Schumacher D; Hackenberger CP; Leonhardt H; Helma J
J Clin Immunol; 2016 May; 36 Suppl 1():100-7. PubMed ID: 27003914
[TBL] [Abstract][Full Text] [Related]
51. [Advances in the study of site-specific antibody-drug conjugates].
Sun Y; Huang R; Sun BW
Yao Xue Xue Bao; 2015 Oct; 50(10):1225-31. PubMed ID: 26837166
[TBL] [Abstract][Full Text] [Related]
52. Sculpting a Uniquely Reactive Cysteine Residue for Site-Specific Antibody Conjugation.
Hwang D; Nilchan N; Park H; Roy RN; Roush WR; Rader C
Bioconjug Chem; 2022 Jun; 33(6):1192-1200. PubMed ID: 35584359
[TBL] [Abstract][Full Text] [Related]
53. Current ADC Linker Chemistry.
Jain N; Smith SW; Ghone S; Tomczuk B
Pharm Res; 2015 Nov; 32(11):3526-40. PubMed ID: 25759187
[TBL] [Abstract][Full Text] [Related]
54. The Recent Developments of ADCs with the Tubulysins as the Payloads.
Xiangrong X; Yao L; Yao A
Mini Rev Med Chem; 2023; 23(18):1797-1805. PubMed ID: 36825713
[TBL] [Abstract][Full Text] [Related]
55. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
Chen H; Lin Z; Arnst KE; Miller DD; Li W
Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
[TBL] [Abstract][Full Text] [Related]
56. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Tsuchikama K; An Z
Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
[TBL] [Abstract][Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
